A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Liver Disease and in Age-, Weight- and Gender-matched Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 16, 2014

Primary Completion Date

January 21, 2015

Study Completion Date

April 30, 2015

Conditions

Heart Failure

Interventions

DRUG

Vericiguat (BAY1021189)

Oral single dose of 2.5 mg (2 x 1.25 mg immediate release tablet)

Trial Locations (1)

Lübeck